Teva Pharmaceuticals Accelerates Growth Strategy with Branded Drugs and Biosimilars
Teva Pharmaceutical Industries (NYSE:TEVA) is accelerating its 'Pivot to Growth' strategy, driven by strong performance in branded medicines like AUSTEDO and AJOVY. CEO Richard Francis highlighted momentum across key growth products, including the potential for AUSTEDO to exceed $3 billion in sales and AJOVY nearing a $1 billion threshold faster than expected. The company is also expanding its biosimilars portfolio with 11 currently on the market and nine more planned by the end of the decade. Teva has reduced debt, achieved investment-grade ratings ahead of schedule, and completed an oversubscribed refinancing recently. The firm's transformation from a generics-focused business to a biopharmaceutical company is supported by strategic partnerships like its deal with Amylyx. Teva expects continued momentum in branded drugs while maintaining stability in the generics segment. Management emphasized resource allocation and commercial execution as key drivers of success, though it did not provide 2027 guidance at this time.
Tickers: $TEVA
Topics: balance sheet improvement biosimilars branded drugs Pivot to Growth